Found: 13
Select item for more details and to access through your institution.
Inhibition of tissue factor pathway inhibitor (TFPI) by ARC19499 improves clotting of hemophiliac blood.
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Follow-up Imaging Studies in Children with Splenic Injuries.
- Published in:
- Clinical Pediatrics, 1999, v. 38, n. 5, p. 273, doi. 10.1177/000992289903800504
- By:
- Publication type:
- Article
Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans.
- Published in:
- AAPS Journal, 2024, v. 26, n. 4, p. 1, doi. 10.1208/s12248-024-00952-4
- By:
- Publication type:
- Article
Hospital- and Patient-Level Characteristics and the Risk of Appendiceal Rupture and Negative Appendectomy in Children.
- Published in:
- JAMA: Journal of the American Medical Association, 2004, v. 292, n. 16, p. 1977, doi. 10.1001/jama.292.16.1977
- By:
- Publication type:
- Article
A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 4, p. 655, doi. 10.1002/cpt.1111
- By:
- Publication type:
- Article
The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-82747-7
- By:
- Publication type:
- Article
The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-68125-9
- By:
- Publication type:
- Article
The aptamer ARC1779 blocks von Willebrand factor–dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
- Published in:
- Transfusion, 2010, v. 50, n. 5, p. 1079, doi. 10.1111/j.1537-2995.2009.02554.x
- By:
- Publication type:
- Article
Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
- Published in:
- Transfusion, 2009, v. 49, n. 10, p. 2181, doi. 10.1111/j.1537-2995.2009.02232.x
- By:
- Publication type:
- Article
Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 4, p. 430, doi. 10.1002/ajh.23106
- By:
- Publication type:
- Article
Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 1, p. 87, doi. 10.1002/ajh.21881
- By:
- Publication type:
- Article
Nonoperative Management of Neonatal Splenic Rupture.
- Published in:
- American Surgeon, 2004, v. 70, n. 12, p. 1085, doi. 10.1177/000313480407001211
- By:
- Publication type:
- Article
An Anti-von Willebrand Factor Aptamer Reduces Platelet Adhesion Among Patients Receiving Aspirin and Clopidogrel in an Ex Vivo Shear-Induced Arterial Thrombosis.
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2011, v. 17, n. 6, p. E70, doi. 10.1177/1076029610384114
- By:
- Publication type:
- Article